Pathophysiology of Transfusional Iron Overload: Contrasting Patterns in Thalassemia Major and Sickle Cell Disease

REFERENCES

• Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in β-thalassemia major. Blood. 2008;111:583–587.
   PubMed Web of Science ®Google Scholar
• Cohen A, Porter J. Transfusion and Iron Chelation Therapy in Thalassemia and Sickle Cell Anemia. Cambridge: Cambridge University Press; 2001.
   Google Scholar
• Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136:501–508.
   PubMed Web of Science ®Google Scholar
• Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80:168–176.
   PubMed Web of Science ®Google Scholar
• Wolfe L, Olivieri N, Sallan D, et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med. 1985;312:1600–1603.
   PubMed Web of Science ®Google Scholar
• Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989;2:27–30.
   Google Scholar
• Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major [see comments]. N Engl J Med. 1994;331:567–573.
   PubMed Web of Science ®Google Scholar
• Modell B, Mathews R. Thalassaemia in Britain and Australia. Birth Defects original article series 1976;12:13–29.
   Google Scholar
• Buja LM, Roberts WC. Iron in the heart. Etiology and clinical significance. Am J Med. 1971;51:209–221.
   PubMed Web of Science ®Google Scholar
• Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood. 2003;101:4632–4639.
   PubMed Web of Science ®Google Scholar
• Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood. 2004;104:263–269.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994;331:574–578.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187–1193.
   PubMed Web of Science ®Google Scholar
• Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. J Cardiovasc Magn Reson. 2009;1(Suppl. 1): O2:1–2.
   Google Scholar
• Wood JC, Claster S, Carson S, et al. Vitamin D deficiency, cardiac iron and cardiac function in thalassaemia major. Br J Haematol. 2008;141:891–894.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol. 2004;124:114–117.
   PubMed Web of Science ®Google Scholar
• Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 2002;100:17–21.
   PubMed Web of Science ®Google Scholar
• Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000;343:327–331.
   PubMed Web of Science ®Google Scholar
• Porter JB, Huehns ER. Transfusion and exchange transfusion in sickle cell anaemias, with particular reference to iron metabolism. Acta Haematol. 1987;78:198–205.
   PubMed Web of Science ®Google Scholar
• Comer GM, Ozick LA, Sachdev RK, et al. Transfusion-related chronic liver disease in sickle cell anemia. Am J Gastroenterol. 1991;86:1232–1234.
   Google Scholar
• Harmatz P, Butensky E, Quirolo K, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000;96:76–79.
   Google Scholar
• Olivieri NF. Progression of iron overload in sickle cell disease. Semin Hematol. 2001;38:57–62.
   PubMed Web of Science ®Google Scholar
• Darbari DS, Kple-Faget P, Kwagyan J, Rana S, Gordeuk VR, Castro O. Circumstances of death in adult sickle cell disease patients. Am J Hematol. 2006;81:858–863.
   PubMed Web of Science ®Google Scholar
• Porter JB. Concepts and goals in the management of transfusional iron overload. Am J Hematol. 2007;82:1136–1139.
   PubMed Web of Science ®Google Scholar
• Westwood MA, Shah F, Anderson LJ, et al. Myocardial tissue characterization and the role of chronic anemia in sickle cell cardiomyopathy. J Magn Reson Imaging. 2007;26:564–568.
   Google Scholar
• Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103:1934–1936.
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Butensky E, Fung E, et al. Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol. 2005;80:70–74.
   PubMed Web of Science ®Google Scholar
• Marx JJM, van Asbeck BS. Use of chelators in preventing hydroxyl radical damage: adult respiratory distress syndrome as an experimental model for the treatment of oxygen-radical-mediated tissue damage. Acta Haematol. 1996;95:49–62.
   PubMed Web of Science ®Google Scholar
• Kornbrust DJ, Mavis RD. Microsomal lipid peroxidation. 1. Characterisation of the role of iron and NADPH. Mol. Pharmacol. 1980;17:400–407.
   PubMed Web of Science ®Google Scholar
• Bacon BR, Tavill AS, Brittenham GM, Park CH, Recknagel RO. Hepatic lipid peroxidation in vivo in rats with chronic iron overload. J Clin Invest. 1983;71:429–439.
   PubMed Web of Science ®Google Scholar
• Myers BM, Prendergast FG, Holman R, Kuntz SM, LaRusso NF. Alterations in the structure, physicochemical properties, and pH of hepatocyte lysosomes in experimental iron overload. J Clin Invest. 1991;88:1207–1215.
   PubMed Web of Science ®Google Scholar
• Link G, Pinson A, Hershko C. Iron loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility. J Lab Clin Med. 1993;121:127–134.
   PubMed Web of Science ®Google Scholar
• Link G, Saada A, Pinson A, Konijn AM, Hershko C. Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells. J Lab Clin Med. 1998;131:466–474.
   PubMed Web of Science ®Google Scholar
• Zhao M, Laissue JA, Zimmermann A. Hepatocyte apoptosis in hepatic iron overload diseases. Histol Histopathol. 1997;12:367–374.
   PubMed Web of Science ®Google Scholar
• Jacob AK, Hotchkiss RS, Swanson PE, Tinsley KW, Karl IE, Buchman TG. Injection of iron compounds followed by induction of the stress response causes tissue injury and apoptosis. Shock. 2000;14:460–464.
   Google Scholar
• Houglum K, Filip M, Witztum JL, Chojkier M. Malondialdehyde and 4-hydroxynonenal protein adducts in plasma and liver of rats with iron overload. J Clin Invest. 1990;86(6):1991–1998.
   Google Scholar
• Parola M, Pinzani A, Casini E, et al. Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increased procollagen (I) gene expression in human fat storing cells. J Biol Chem. 1993;264:16957–16962.
   Google Scholar
• Bissell DM, Wang SS, Jarnagin WR, Roll FJ. Cell specific expression of transforming growth factor-ß in the rat liver. J Clin Invest. 1995;96:447–455.
   PubMed Web of Science ®Google Scholar
• Grootveld M, Bell JD, Halliwell B, Aruoma OI, Bomford A, Sadler PJ. Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J Biol Chem. 1989;264:4417–4422.
   PubMed Web of Science ®Google Scholar
• Evans RW, Rafique R, Zarea A, et al. Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera. J Biol Inorg Chem. 2008;13:57–74.
   Google Scholar
• Gutteridge J, Halliwell B. Iron toxicity and oxygen radicals. Baillieres Clin Haematol. 1989;2:195–256.
   PubMedGoogle Scholar
• Brissot P, Bolder U, Schteingart CD, Arnaud J, Hofmann AF. Intestinal absorption and enterohepatic cycling of biliary iron originating from plasma non-transferrin-bound iron in rats. Hepatology. 1997;25:1457–1461.
   Google Scholar
• Link G, Pinson A, Kahane I, Hershko C. Iron loading modifies the fatty acid composition of cultured rat myocardial cells and liposomal vesicles: effect of ascorbate and alpha-tocopherol on myocardial lipid peroxidation. J Lab Clin Med. 1989;114:243–249.
   PubMedGoogle Scholar
• Oudit GY, Sun H, Trivieri MG, et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med. 2003;9:1187–1194.
   PubMed Web of Science ®Google Scholar
• Liuzzi JP, Aydemir F, Nam H, Knutson MD, Cousins RJ. Zip14 (Slc39a14) mediates non-transferrin-bound iron uptake into cells. Proc Natl Acad Sci U S A. 2006;103:13612–13617.
   PubMed Web of Science ®Google Scholar
• Shah F, Westwood MA, Evans PJ, Porter JB. Discordance in MRI assessment of iron distribution and plasma NTBI between transfusionally iron loaded adults with sickle cell and thalassaemia syndromes. Blood. 2002;100:468a.
   Google Scholar
• Walter PB, Fung EB, Killilea DW, et al. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol. 2006;135:254–263.
   PubMed Web of Science ®Google Scholar
• Porter J, Cappellini M, El-Beshlawy A, et al. Effect of deferasirox (Exjade®) on labile plasma iron levels in heavily iron-overloaded patients with transfusion-dependent anemias enrolled in the large-scale, prospective 1-year EPIC trial. Blood. 2008;112: Abstract 3881.
   Google Scholar
• Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090–2093.
   PubMed Web of Science ®Google Scholar
• Nemeth E. Iron regulation and erythropoiesis. Curr Opin Hematol. 2008;15:169–175.
   PubMed Web of Science ®Google Scholar
• Lin L, Valore EV, Nemeth E, Goodnough JB, Gabayan V, Ganz T. Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood. 2007;110:2182–2189.
   PubMed Web of Science ®Google Scholar
• Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 2007;92:583–588.
   PubMed Web of Science ®Google Scholar
• Kattamis A, Papassotiriou I, Palaiologou D, et al. The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica. 2006;91:809–12.
   PubMed Web of Science ®Google Scholar
• Shah FT. The relationship between non transferrin bound iron and iron overload in thalassaemia and sickle syndromes. MD Thesis, University of London; 2008.
   Google Scholar
• Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13:1096–1101.
   PubMed Web of Science ®Google Scholar
• Sayani F, Bansal S, Evans P, Weljie A, Hider RC, Porter JB. Disease specific modulation of serum hepcidin: Impact of GDF-15 and iron metabolism markers in thalassemia major, thalassemia intermedia and sickle cell disease: A univariate and multivariate analysis. Blood. 2008;112: Abstract 3850.
   Google Scholar
• Delaby C, Pilard N, Goncalves AS, Beaumont C, Canonne-Hergaux F. Presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and down-regulated by hepcidin. Blood. 2005;106:3979–3984.
   PubMed Web of Science ®Google Scholar
• Knutson MD, Oukka M, Koss LM, Aydemir F, Wessling-Resnick M. Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc Natl Acad Sci U S A. 2005;102:1324–1328.
   PubMed Web of Science ®Google Scholar
• Jacolot S, Ferec C, Mura C. Iron responses in hepatic, intestinal and macrophage/monocyte cell lines under different culture conditions. Blood Cells Mol Dis. 2008;41:100–108.
   PubMed Web of Science ®Google Scholar
• Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8:1383–1389.
   PubMed Web of Science ®Google Scholar
• Nath KA, Grande JP, Haggard JJ, et al. Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. Am J Pathol. 2001;158:893–903.
   PubMed Web of Science ®Google Scholar
• Flanagan JM, Steward S, Hankins JS, Howard TM, Neale G, Ware RE. Microarray analysis of liver gene expression in iron overloaded patients with sickle cell anemia and beta-thalassemia. Am J Hematol. 2009;84:328–334.
   Google Scholar